Aker BioMarine (OB:AKBM) Stock Faces Ongoing Losses As Q2 Profitability Lags Bullish Narratives

Aker BioMarine (OB:AKBM) has just posted its Q2 2026 numbers, with revenue of US$57.9 million and a net income loss from continuing operations of US$5.2 million, while the trailing twelve months show total revenue of US$227.2 million and a net income loss of US$10 million. Over recent quarters the company has seen quarterly revenue move between US$50.8 million and US$57.9 million and quarterly net income swing between a profit of US$2.5 million and a loss of US$5.2 million. This underscores how volatile profitability has been. For investors, this latest set of results keeps the focus firmly on when margins can stabilise and whether the current pressure on earnings can ease.

See our full analysis for Aker BioMarine.

With the headline figures on the table, the next step is to compare these results with the prevailing narratives around Aker BioMarine to see which stories the numbers support and which ones they push back against.

See what the community is saying about Aker BioMarine

Revenue Holds Around US$57 Million, Margins Still Under Pressure

• Q2 2026 revenue came in at US$57.9 million, close to the past few quarters in this range, while Aker BioMarine reported a loss from continuing operations of US$5.2 million and a trailing twelve month loss of US$10 million, so the top line is steady but profitability is still weak.
• Consensus narrative expects revenue to grow around 11.9% per year with earnings improving strongly, yet the trailing twelve month net loss of US$10 million and a five year pattern of widening losses mean the current figures still reflect the concerns about earnings durability rather than the growth path analysts are discussing.
  • Analysts in the balanced view point to potential margin improvement, but the latest quarterly loss and the absence of positive net margins over the past year show that shift has not occurred in the reported numbers yet.
  • The mix of stable quarterly revenue between US$50.8 million and US$57.9 million and continued losses suggests that, for now, any margin recovery in the consensus story remains a forward looking expectation rather than something visible in current earnings.

Losses Persist Despite Trailing US$227.2 Million Revenue

• Over the trailing twelve months Aker BioMarine generated US$227.2 million of revenue but still reported a net loss from continuing operations of US$10 million, and historical data show losses have grown at an annualised rate of 24.4% over the past five years.
• Bulls focus on forecast earnings growth of 106.54% per year and expectations of profitability within three years, yet the current trailing loss and multi year pattern of growing losses set a high bar for that bullish view.
  • Supporters of the bullish narrative highlight new products and potential margin expansion, but the trailing net loss and lack of positive net margins over the last year give little numerical evidence so far that these drivers are flowing through the income statement.
  • The contrast between strong projected growth and the existing loss profile means investors who lean bullish will likely watch closely for any shift from quarterly losses like the US$5.2 million in Q2 2026 toward consistent profits in upcoming reports.

Have a closer look at how bullish investors frame these numbers and where they think the real turning points could come through 🐂 Aker BioMarine Bull Case.

Valuation Gap vs DCF Fair Value, But Premium P/S Multiple

• The data show Aker BioMarine trading at a P/S ratio of 3.8x compared with a peer average of 1.3x and a Norwegian Food industry average of 2.1x, while a model based DCF fair value of NOK338.60 sits far above the current share price of NOK97.30.
• Bears point out that the stock looks expensive on P/S despite being unprofitable, and the combination of a 3.8x sales multiple with trailing losses challenges the idea that the wide gap to the DCF fair value alone makes the case compelling.
  • Critics highlight that the company has not produced positive net margins over the past year, so the higher P/S multiple is currently backed by revenue rather than earnings, which aligns with the more cautious narrative around valuation risk.
  • At the same time, the sizeable difference between the recent market price and the DCF fair value of NOK338.60 means investors weighing the bearish concerns are also deciding how much weight to give to model based upside versus the premium sales multiple and ongoing losses.

Skeptical investors often focus on this valuation tension, and the bearish narrative sets out why they think the current P/S multiple and loss profile matter so much 🐻 Aker BioMarine Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Aker BioMarine on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With so many contrasting views around Aker BioMarine, the key question is which story you think the numbers support. Act quickly by reviewing the underlying figures, then weigh them against the 2 key rewards

See What Else Is Out There Beyond Aker BioMarine

Aker BioMarine is generating stable revenue but continues to report losses, with profitability and margins not yet matching the optimistic growth stories around the stock.

If you are concerned about ongoing losses and want ideas where profitability and balance sheets do more of the heavy lifting right now, check out the solid balance sheet and fundamentals stocks screener (419 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com